News >

Expert Discusses Dramatic Larotrectinib Data in Pediatric Cancer

Angelica Welch
Published: Friday, Apr 06, 2018

Ramamoorthy Nagasubramanian, MD
Ramamoorthy Nagasubramanian, MD
Recent results published in The Lancet Oncology showed that larotrectinib induced an objective response rate (ORR) of 93% in pediatric patients with TRK fusion-positive solid tumors. These results have set a new precedent for the simultaneous development of agents in pediatric and adult patients, said Ramamoorthy Nagasubramanian, MD, one of the investigators on the study.

“From my personal experience, I can tell that this is going to be the favored treatment upfront for these patients who have unresectable disease or primary refractory disease,” said Nagasubramanian.

This multicenter, open-label study enrolled 24 patients aged 1 month to 21 years who had been diagnosed with locally advanced or metastatic solid tumors or central nervous system tumors that had relapsed, progressed, or were nonresponsive to available therapies.

A rolling submission of a new drug application to the FDA was completed in March 2018 for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

In an interview with OncLive, Nagasubramanian, chief, Division of Hematology/Oncology, Department of Pediatrics, Nemours Children’s Health System, discussed the results of this phase I/II study of larotrectinib in pediatric patients.

OncLive: Can you provide some background information on the trial?

Nagasubramanian: Initially, when this trial opened, it was open to children with solid tumors who were advanced and either refractory, or not responding to primary frontline treatments. Since we knew that this drug was an agent targeted toward TRK fusions, we knew that we would find some pediatric tumors that carry these fusions and may respond well. We did not know the actual incidence of TRK fusions in pediatric cancers, so the study initially started enrolling all patients with solid tumors. We knew that there were some rare pediatric tumors that harbored TRK fusions, so we hoped to see those patients included on the trial, which was the case. 

Having tested the initial group of pediatric patients, out of the 24 patients, 17 had TRK fusion–containing tumor types, whereas the other 7 did not have TRK fusions. We found that there were no responses in patients whose tumors did not carry this fusion, which makes sense because it was a targeted therapy. However, in patients who harbored NTRK fusions of any combination, there was a very higher response rate. In this analysis, there was a 93% response rate in those patients.

What was the design of the study?

It was a phase I/II study. The phase I [portion] was meant to look at the safety in children. There was a trial in adults of the same drug and similar plan, and because there was knowledge about needs for pediatric drugs in rare cancer, this trial was conducted. The phase I study was a dose-finding study as well, and there were no major safety issues. The dose-finding phase was done with 2 cohorts of patients, and we came up with the recommended phase II dose, which is what was used in the rest of the patients in the study. We found a tolerated dose, and did not see any high rates of toxicities, which is unlike what we normally see.

We were able to achieve what is called the "adult equivalent dose," and see objective responses at that dose, although it was not a maximally targeted dose. There was no need to give more because we were already seeing responses. Once we had safety and dose established, we opened a phase II part of the trial to enroll patients, especially those with TRK fusions.

What were the results, and how did they impact the pediatric cancer community?

The results showed a very high ORR of larotrectinib in pediatric tumors that harbored a TRK fusion. Of the 15 patients evaluable, there were 4 complete responses without evidence of disease, and there were 10 partial responses, with a significant shrinkage in tumor size. This is amazing for an orally administered drug with little side effects—it has the potential to change the paradigm of how we treat infantile fibrosarcoma that is initially not resectable.

Traditionally, those children received chemotherapy and then would undergo surgery if they responded to chemotherapy. Chemotherapy is genotoxic and has both short- and long-term side effects. Whereas, with larotrectinib, we can achieve better results—the response rate to chemotherapy is not even close to 93%. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x